M. Cheung

发表

Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.

P. A. Harris, J. Veal, Liping Wang, 2005, Journal of medicinal chemistry.

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.

P. A. Harris, J. Veal, Rakesh Kumar, 2008, Journal of medicinal chemistry.

Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).

Brian J. Wilson, L. Shewchuk, P. Sabbatini, 2009, Bioorganic & medicinal chemistry letters.

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4.

Carl A. Brooks, D. Holt, W. Bao, 2017, ACS medicinal chemistry letters.

PROPERTIES OF THE TRPV4 AGONIST GSK1016790A AND the TRPV4 ANTAGONIST GSK2193874.

D. Holt, R. Willette, K. Thorneloe, 2017, Physiological reviews.

PROPERTIES OF THE TRPV4 ACTIVATOR GSK1016790A AND THE TRPV4 ANTAGONIST GSK2193874

D. Holt, R. Willette, K. Thorneloe, 2017 .

Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity

M. Gershon, B. Greenwood-Van Meerveld, M. Cheung, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.

G. Joberty, N. Zinn, M. Cheung, 2018, ACS medicinal chemistry letters.

Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice

C. Miller, L. Harrington, T. Gilmer, 2005 .

TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis.

J. Foley, N. Laping, J. Cottom, 2017, Blood advances.

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

C. Miller, M. Cheung, J. Stafford, 2004, British Journal of Cancer.

Pyrazolo[1,5-a]pyridines as p38 kinase inhibitors.

P. A. Harris, M. Cheung, M. Peel, 2005, Organic letters.

Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).

D. Holt, A. P. Graves, L. Shewchuk, 2015, Journal of medicinal chemistry.

Identi fi cation of Purines and 7 ‐ Deazapurines as Potent and Selective Type I Inhibitors of Troponin I ‐ Interacting Kinase ( TNNI 3 K )

D. Holt, A. P. Graves, L. Shewchuk, 2015 .

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

Kyle A. Emmitte, Masaaki Furuta, N. Noro, 2007, Molecular Cancer Therapeutics.

Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors.

M. Jaye, J. Trill, R. Annan, 2009, Bioorganic & medicinal chemistry letters.

Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.

R. Keenan, M. Cheung, A. Oliff, 2021, ACS medicinal chemistry letters.

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Ming-Chih Crouthamel, L. Harrington, T. Gilmer, 2007, Molecular Cancer Therapeutics.

TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury.

S. Matalon, S. Jordt, R. Willette, 2014, American journal of physiology. Lung cellular and molecular physiology.

Function and Oxygen Saturation in Chemically Induced Acute Lung Injury

S. Matalon, S. Jordt, H. Bradshaw, 2014 .

TRPV 4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury

S. Matalon, S. Jordt, R. Willette, 2014 .

Development of a high-throughput screen to detect inhibitors of TRPS1 sumoylation.

Susheel Kumar, T. Meek, L. Szewczuk, 2013, Assay and drug development technologies.

Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations

R. Latorre, B. Greenwood-Van Meerveld, M. Cheung, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

An Orally Active TRPV4 Channel Blocker Prevents and Resolves Pulmonary Edema Induced by Heart Failure

H. Alsaid, W. Bao, R. Willette, 2012, Science Translational Medicine.

Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.

J. Jackson, T. J. Lansing, R. Mook, 2009, Bioorganic & medicinal chemistry letters.

Efficacy of GSK461364, a selective Plk1 inhibitor, in human tumor xenograft models

J. Jackson, A. Gilmartin, Pearl S Huang, 2007 .

Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.

J. Jackson, M. Cheung, Ronda G. Davis-Ward, 2010, Bioorganic & medicinal chemistry letters.

Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms

H. Kleinman, Jeffrey E. Green, Rakesh Kumar, 2005, Oncogene.

Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).

Carl A. Brooks, D. Holt, D. Behm, 2019, ACS medicinal chemistry letters.

Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1.

V. Tirunagaru, M. Cheung, Raghuram S. Tangirala, 2018, ACS medicinal chemistry letters.

A Novel Acyl-CoA: Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor, GSK2973980A, Inhibits Postprandial Triglycerides and Reduces Body Weight in a Rodent Diet-induced Obesity Model

Douglas W. Thomson, G. Bergamini, A. Awasthi, 2017 .

Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms

H. Kleinman, Jeffrey E. Green, Rakesh Kumar, 2005, Oncogene.

Optimization of a Novel Series of TRPV4 Antagonists with In Vivo Activity in a Model of Pulmonary Edema.

K. Thorneloe, M. Cheung, T. Roethke, 2013, ACS medicinal chemistry letters.

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf.

D. Holt, A. P. Graves, L. Shewchuk, 2021, Journal of medicinal chemistry.